MedTrace Logo

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

NCT00990808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2015-06-04

No results posted yet for this study

Summary

This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.

Conditions

Interventions

DRUG

anacetrapib

\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.

DRUG

Comparator: atorvastatin

Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.

DRUG

Comparator: placebo to MK0859

Placebo to MK0859 once daily for 4 weeks.

DRUG

Comparator: placebo to atorvastatin

Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-06-30
Completion
2011-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00990808 on ClinicalTrials.gov